Complete financial analysis of SanBio Company Limited (4592.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SanBio Company Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Guangdong Modern High-tech Fiber Co., Ltd (300876.SZ) Income Statement Analysis – Financial Results
- Kudelski SA (0QNQ.L) Income Statement Analysis – Financial Results
- Kotobukiya Co., Ltd. (7809.T) Income Statement Analysis – Financial Results
- ADC Therapeutics SA (ADCT) Income Statement Analysis – Financial Results
- Alviva Holdings Limited (ALVNF) Income Statement Analysis – Financial Results
SanBio Company Limited (4592.T)
About SanBio Company Limited
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 447.23M | 741.61M | 490.51M | 949.54M | 1.17B | 3.23B | 204.29M |
| Cost of Revenue | 14.50M | 24.62M | 132.47M | 74.46M | 446.78M | 740.87M | 53.67M | 17.17M | 14.14M | 0.00 | 0.00 |
| Gross Profit | -14.50M | -24.62M | -132.47M | -74.46M | 447.00K | 741.00K | 436.84M | 932.38M | 1.16B | 3.23B | 204.29M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.10% | 0.10% | 89.06% | 98.19% | 98.80% | 100.00% | 100.00% |
| Research & Development | 2.85B | 6.12B | 4.96B | 4.07B | 4.33B | 3.72B | 4.16B | 2.06B | 1.70B | 623.42M | 530.28M |
| General & Administrative | 0.00 | 1.78B | 1.67B | 1.73B | 1.61B | 754.49M | 712.79M | 806.26M | 604.10M | 357.05M | 258.25M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.69B | 1.78B | 1.67B | 1.73B | 1.61B | 754.49M | 712.79M | 806.26M | 604.10M | 357.05M | 258.25M |
| Other Expenses | 0.00 | -2.30M | 328.00K | 237.00K | 493.10M | 950.87M | 680.00M | 203.00K | -18.28M | -1.11M | 71.00K |
| Operating Expenses | 4.54B | 7.90B | 6.62B | 5.80B | 5.93B | 4.48B | 4.87B | 2.86B | 2.30B | 980.46M | 788.53M |
| Cost & Expenses | 4.54B | 7.90B | 6.62B | 5.80B | 5.93B | 4.48B | 4.87B | 2.88B | 2.30B | 980.46M | 788.53M |
| Interest Income | 2.47M | 4.01M | 2.24M | 2.47M | 9.07M | 13.06M | 24.77M | 8.61M | 1.86M | 272.00K | 344.00K |
| Interest Expense | 25.81M | 25.27M | 44.61M | 47.17M | 47.36M | 33.84M | 26.14M | 12.55M | 18.13M | 5.42M | 0.00 |
| Depreciation & Amortization | 14.50M | 24.62M | 132.47M | 74.46M | 39.64M | 36.86M | 53.67M | 26.76M | 14.14M | 5.63M | 4.30M |
| EBITDA | -4.53B | -4.62B | -4.37B | -5.73B | -5.06B | -2.79B | -3.79B | -2.10B | -1.14B | 2.24B | -585.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,131.32% | -384.19% | -788.58% | -223.99% | -97.06% | 69.35% | -284.62% |
| Operating Income | -4.54B | -7.90B | -6.62B | -5.80B | -5.49B | -3.73B | -4.38B | -1.93B | -1.13B | 2.25B | -584.24M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,226.69% | -503.49% | -892.62% | -203.49% | -95.79% | 69.64% | -285.99% |
| Total Other Income/Expenses | 2.00B | 3.20B | 2.06B | 2.59B | 329.56M | 814.57M | 439.26M | -233.99M | -47.16M | -20.47M | -5.15M |
| Income Before Tax | -2.54B | -4.70B | -4.56B | -3.21B | -5.16B | -2.92B | -3.94B | -2.17B | -1.17B | 2.23B | -589.39M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,153.00% | -393.65% | -803.07% | -228.13% | -99.81% | 69.00% | -288.51% |
| Income Tax Expense | 102.00M | 862.14M | 117.43M | 174.38M | 1.21M | 1.21M | 1.21M | -330.92M | -184.01M | 492.01M | 64.00K |
| Net Income | -2.64B | -5.56B | -4.68B | -3.39B | -5.16B | -2.92B | -3.94B | -1.84B | -988.40M | 1.74B | -589.45M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,153.27% | -393.81% | -803.31% | -193.28% | -84.14% | 53.77% | -288.54% |
| EPS | -40.48 | -95.99 | -90.33 | -65.38 | -100.91 | -60.17 | -86.85 | -40.88 | -22.67 | 44.31 | -15.41 |
| EPS Diluted | -40.48 | -95.99 | -90.33 | -65.38 | -100.91 | -60.17 | -86.85 | -40.88 | -22.67 | 44.31 | -15.41 |
| Weighted Avg Shares Out | 65.32M | 57.92M | 51.79M | 51.79M | 51.11M | 48.54M | 45.37M | 44.89M | 43.60M | 39.18M | 38.25M |
| Weighted Avg Shares Out (Dil) | 65.32M | 57.92M | 51.79M | 51.79M | 51.11M | 48.54M | 45.37M | 44.89M | 43.60M | 39.18M | 38.25M |
Source: https://incomestatements.info
Category: Stock Reports